SLC5A2 and diabetes mellitus: For older patients with diabetes mellitus who have concurrent established/high risk of ASCVD, priority should be given to glucose‐lowering medications with cardiovascular protective effects, including GLP‐1RAs or SGLT‐2 inhibitors with evidence‐based medicine support.